Two new studies by scientists at Scripps Research are bringing Ebola virus’s weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection—not only for Ebola virus, but for other closely related pathogens as well.
The research suggests antibodies like these could be key ingredients in versatile lifesaving therapeutics capable of neutralizing all members of the Ebolavirus genus.
“This is like understanding how to kill five or six birds with one stone,” says Erica Ollmann Saphire, PhD, professor at Scripps Research and senior author of the new papers, published recently in mBio and the Journal of Infectious Diseases. “The different viruses in the Ebolavirus genus vary in their structure, but all these different viruses have the same outbreak potential. We need a therapeutic approach that can target them all.”
A major challenge in treating what we call Ebola virus is that it isn’t just one pathogen but five. Members of the genus Ebolavirus include Ebola virus, Sudan virus, Bundibugyo virus, Taï Forest virus and Reston virus. Each of these viruses is up to 50 percent different in amino acid sequence, making it tough to develop broad treatment strategies. For example, the Sudan and Bundibugyo viruses were responsible for 40 percent of Ebola cases before 2013, yet current experimental Ebola therapies can’t neutralize them.
Adding to the threat, all members of the Ebolavirus genus could mutate to escape immune system defenses and fight off drug therapies.
The new research shows that antibodies that bind to a site on the viral “fusion loop” can neutralize all known ebolaviruses. The fusion loop is part of the machinery that the virus uses to fuse with human cells and initiate infection. Targeting this peptide could present an opportunity to develop a universal therapy for infections caused by all five members of the Ebolavirus genus.
For the mBio study, the researchers focused on a human antibody called ADI-15878. This antibody was found in the blood of an Ebola virus survivor and is the only human antibody ever found to neutralize all five members of the Ebolavirus genus.
So how does ADI-15878 do it?
Using a high-resolution structural technique called X-ray crystallography, the scientists modeled the interaction between the antibody and the viral glycoprotein (the protein that enables the virus to infect a cell). Ebola’s glycoprotein is covered with sugars that help to mask the virus from detection by the body’s immune system. The team observed that ADI-15878 binds directly to one of these sugars alongside a paddle-like structure on the fusion loop. Part of the antibody then dips down and binds into a pocket that is normally hidden by another part of the viral glycoprotein.
“It’s really cool to see that this antibody has found a way to bind into a cryptic, conserved pocket despite the proximity of sugars and other pieces of the virus that effectively hide this region from the immune system” says mBio study first author Brandyn West, PhD, a research associate at Scripps Research.
The researchers hypothesize that this action locks two important parts of Ebola’s fusion machinery together, making it impossible for the virus to get into human cells. The fusion loop is a key piece of the Ebola virus entry machinery, so its structure is what scientists refer to as highly conserved—meaning the virus can’t easily mutate the fusion loop to escape immune detection without compromising the ability of the virus to infect cells. If antibodies targeting this structure were included in therapies or elicited through vaccines, these antibodies should provide broad protection.
But was ADI-15878 just a one in a million antibody from a lucky human survivor?
The second paper the lab published this week in the Journal of Infectious Diseases shows that such antibodies are not out of reach. In this work, the scientists showed that a mouse which had been sequentially immunized with Ebola virus and then Sudan virus also had a broadly protective antibody response. The researchers demonstrate that an antibody, termed 6D6, from this mouse binds to the same region as ADI-15878. The immunization study provides more evidence that this part of the fusion loop is a promising target for vaccine design and therapies.
“Both the human and mouse antibodies were able to neutralize all known types of Ebola,” explains Jacob Milligan, PhD, research associate at Scripps Research and first author of the Journal of Infectious Diseases study.
It could be possible, the researchers say, for therapeutics to include antibodies that work like ADI-15878. Researchers working on Ebola vaccines could also design molecules that look like this region of the fusion loop. These molecules, called immunogens, teach the human immune system which piece of the virus to target.
“We’re hot on the trail of immunogen design strategies to produce more of these neutralizing antibodies,” Ollmann Saphire says.
The Latest on: Immunogens
via Google News
The Latest on: Immunogens
- GeoVax Presenting at Upcoming October European Scientific Conferenceson October 15, 2019 at 6:00 am
On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The ...
- ImmunoGen's TDM-1 Looks Strong at ESMOon October 5, 2019 at 2:17 pm
Updates with recent stock price. BOSTON ( TheStreet) -- The "armed antibody" drug TDM-1 under development by Roche and ImmunoGen ( IMGN - Get Report) posted a higher response rate and lower toxicity ...
- Creating antibodies with antibodieson September 15, 2019 at 5:00 pm
However, the production of bNabs is difficult to elicit via vaccines because their germline progenitors do not bind HIV-derived vaccine immunogens, preventing bNab maturation. Traditionally, vaccines ...
- Broadening vaccine strategies to induce HIV broadly neutralizing antibodieson August 13, 2019 at 5:00 pm
Despite multiple targets of bNAb on HIV-1 envelope protein (Env) being identified, to date diverse vaccine approaches of specific structure-based Env immunogens have failed to induce protective bNAbs ...
- Scripps CHAVD wins $129 million NIH grant to advance new HIV vaccine approachon July 11, 2019 at 1:02 pm
Using that knowledge, they developed immunogens (molecules that spur an immune reaction in the body) that in animal studies demonstrated the ability to elicit production of anti-HIV bnAbs or their ...
- Peripheral TREM1 responses to brain and intestinal immunogens amplify stroke severityon July 1, 2019 at 8:10 am
Fig. 1: TREM1 is induced on peripheral myeloid cells that infiltrate the ischemic brain. Fig. 2: TREM1 is elevated in peripheral infiltrating myeloid cells early after MCAo. Fig. 3: Genetic ablation ...
- The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogenson April 16, 2019 at 7:17 am
That the human and simian immunodeficiency virus envelope glycoproteins are not ideal immunogens is an expected consequence of the immunological selective forces that drive the evolution of these ...
- Conformation of the native HIV-1 envelope protein raises questions for vaccine designon April 10, 2019 at 10:06 am
1). Defining the diverse structures of the Env trimer is key to understanding the host’s neutralizing-antibody response and to developing vaccines based on Env-derived immunogens — the proteins that ...
- Immuno-Oncology Company Elicio Therapeutics Launches with Novel Vaccine & Immunotherapy Platform to Treat an Array of Cancerson March 27, 2019 at 6:33 am
Elicio’s Amphiphile platform enables, for the first time, precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body’s own system of immune ...
via Bing News